title: Therapy of Canine Hyperlipidemia with Bezafibrate.
abstract: BACKGROUND
  Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs.
  
  
  OBJECTIVE
  To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations.
  
  
  METHODS
  Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]).
  
  
  METHODS
  Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared.
  
  
  RESULTS
  Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment.
  
  
  CONCLUSIONS
  Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.
authors.affiliation: University of Santo Amaro, São Paulo, Brazil.|University of Guarulhos, São Paulo, Brazil.
authors.forename: V
authors.initials: V
authors.lastname: De Marco
authors.affiliation: University of Guarulhos, São Paulo, Brazil.
authors.forename: K S M
authors.initials: KSM
authors.lastname: Noronha
authors.affiliation: University of Guarulhos, São Paulo, Brazil.
authors.forename: T C
authors.initials: TC
authors.lastname: Casado
authors.affiliation: Medicine School, University of São Paulo, São Paulo, Brazil.
authors.forename: E R
authors.initials: ER
authors.lastname: Nakandakare
authors.affiliation: Veterinary Medicine School, University of São Paulo, São Paulo, Brazil.
authors.forename: J C
authors.initials: JC
authors.lastname: Florio
authors.affiliation: University of Santo Amaro, São Paulo, Brazil.
authors.forename: E Z
authors.initials: EZ
authors.lastname: Santos
authors.affiliation: University of California, Davis, CA.
authors.forename: C
authors.identifier: http://orcid.org/0000-0003-0393-4135
authors.initials: C
authors.lastname: Gilor
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006949:Hyperlipidemias / Q000188:drug therapy / Q000662:veterinary*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D001629:Bezafibrate
keywords: Cholesterol; Hyperadrenocorticism; Peroxisome proliferator-activated receptor; Schnauzer; Triglyceride